Special Issue

Recent Trends on Enzymes Inhibitors and Activators in Drug Research

Message from the Guest Editor

It is known that enzymes are involved in many pathological conditions, such as inflammation, diabetes, microbial infections, HIV, and neoplastic diseases among others. Enzyme inhibition is universally accepted as a strategy to treat the above mentioned conditions or to alternate the mechanism involved. Thus, the aim of the current Special Issue is to collect and present recent advances in the research fields connected to inhibition of different types of enzymes, such as Cyclooxygenase-1/Cyclooxygenase-2 (COX-1/COX-2.), Lipoxygenase (LOX), Protein tyrosine phosphatase 1B (PTP-1B), Peroxisome Proliferator-Activated Receptor Gamma (PPAR-🖾), reverse transcriptase, integrase, gyrase, MurB, aldose reductase, carbonic anhydrise, etc.

Guest Editor

Prof. Dr. Athina Geronikaki

School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece

Deadline for manuscript submissions

closed (30 April 2018)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/11526

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

